Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Yamamoto: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy.... (0.13 sec) 

Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the …

- diabetesjournals.org
Y Yamamoto, Y Maeshima, H Kitayama, S … - Diabetes, 2004 - Am Diabetes Assoc
In the early stage of diabetic nephropathy (one of the major microvascular
complications of diabetes) glomerular hyperfiltration and hypertrophy are
observed. It is clinically important to regulate glomerular hypertrophy for ...
Cited by 83 - Related articles - BL Direct - All 6 versions

Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type …

- diabetesjournals.org
K Ichinose, Y Maeshima, Y Yamamoto, H … - Diabetes, 2005 - Am Diabetes Assoc
Diabetic nephropathy is one of the major microvascular complications in diabetes
and is the leading cause of end-stage renal disease worldwide. Among various
factors, angiogenesis-associated factors such as vascular endothelial ...
Cited by 40 - Related articles - BL Direct - All 6 versions

Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development


AS Woolf, HT Yuan - Pediatric Nephrology, 2001 - Springer
Abstract Angiopoietin-1 (Ang-1) is a secreted growth factor which binds to and
activates the Tie-2 receptor tyrosine kinase. The factor enhances endothelial
cell survival and capillary morphogenesis, and also limits capillary ...
Cited by 39 - Related articles - BL Direct - All 3 versions

Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial …

- asnjournals.org
SC Satchell, KL Anderson, PW Mathieson - Journal of the American Society of Nephrology, 2004 - Am Soc Nephrol
ABSTRACT. Normal glomerular filtration depends on the combined properties of the
three layers of glomerular capillary wall: glomerular endothelial cells (GEnC),
basement membrane, and podocytes. Podocytes produce endothelial factors, ...
Cited by 65 - Related articles - BL Direct - All 5 versions

Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology.


SC Satchell, PW Mathieson - Journal of nephrology - ncbi.nlm.nih.gov
Angiopoietins are a recently discovered family of growth factors which act on
endothelial cells via Tie receptors. They are widely expressed and have
essential roles in regulating vascular growth, development, maturation and ...
Cited by 43 - Related articles - BL Direct - All 6 versions

Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular …

- asnjournals.org
SC Satchell, SJ Harper, JE Tooke, D … - Journal of the American Society of Nephrology, 2002 - Am Soc Nephrol
ABSTRACT. Vascular endothelial growth factor (VEGF) is abundantly expressed by
podocytes, but its role in glomeruli is unknown. Angiopoietins are endothelial
cell growth factors that function in concert with VEGF but have not ...
Cited by 55 - Related articles - BL Direct - All 4 versions

The impact of experimental diabetes mellitus in rats on glomerular capillary number and …


JR Nyengaard, R Rasch - Diabetologia, 1993 - Springer
Summary. The structural counterpart of the increased glo- merular filtration
found in acute diabetes mellitus and ex- perimental diabetes has been ascribed
to the increased glomerular filtration surface. Using modern design-based ...
Cited by 67 - Related articles - BL Direct - All 3 versions

2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of …

- shouxi.net
K Ichinose, Y Maeshima, Y Yamamoto, M … - Diabetes, 2006 - Am Diabetes Assoc
One of the mechanisms involved in the progression of diabetic nephropathy, the
most common cause of end-stage renal failure, is angiogenic phenomenon
associated with the increase of angiogenic factors such as vascular ...
Cited by 15 - Related articles - BL Direct - All 7 versions

Novel therapeutic approaches for progressive renal disorders by targeting glomerular …


Y Maeshima - Clinical and Experimental Nephrology, 2005 - Springer
The number of patients requiring renal replacement therapy due to end-stage
renal disease (ESRD) is increasing worldwide. In this review, we present our
strategies to de- velop novel therapeutic approaches to halt the ...
Cited by 1 - Related articles - BL Direct - All 3 versions

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 …

- oxfordjournals.org
BF Schrijvers, A Flyvbjerg, RG Tilton, NH … - Nephrology Dialysis Transplantation, 2006 - ERA-EDTA
Background. Antagonism of vascular endothelial growth factor (VEGF) has improved
the outcome in experimental nephropathies of various origins, including diabetic
nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse ...
Cited by 27 - Related articles - BL Direct - All 5 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google